SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently experiencing significant selling pressure as investors express mounting frustration over its multi-year decline, weakening brand relevance, and ongoing challenges in the competitive consumer space. While community sentiment is heavily polarized between those betting on a value-driven turnaround due to a high dividend yield and those aggressively shorting the stock, discussions remain focused on the company's struggle to find a definitive bottom.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently under significant downward pressure as opening arguments begin in a high-profile, multi-state trial alleging the company designed its platforms to be addictive to children. While the community is divided between those viewing the litigation as a money grab or frivolous and others calling for long-term accountability, many investors are actively debating whether to buy the dip or exit the stock amidst broader mega-cap volatility.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending as investors react to a significant revenue beat and ambitious growth projections for its AI infrastructure and cloud computing arm, Quake AI. The community is actively debating the stock's potential for a massive short squeeze, noting a record number of shares sold short against a limited float as institutional interest and data center expansion plans build momentum.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlist is trending as investors rally around the company’s significant legal and commercial momentum, highlighted by a major multi-year patent settlement with Samsung and ongoing litigation against other memory giants. The community is focused on the potential for massive licensing revenue and a projected short squeeze, with long-term holders actively discussing the company’s pivotal role in AI-driven memory infrastructure.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is trending as investors debate whether the recent pullback serves as a strategic buy-the-dip opportunity or a signal of broader weakness in the AI infrastructure sector. While the community remains divided over its valuation, many are focused on the company's critical role in high-speed connectivity and data center growth, closely tracking how it holds key support levels.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon shares are facing intense selling pressure as community sentiment remains deeply divided over the stock's status as a value play versus a terminal value trap. While some investors are aggressively buying the dip, citing deep-value P/E metrics and speculative buyout potential, bears continue to emphasize concerns regarding brand fatigue, recent executive turnover, and perceived decline in product quality.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as institutional investors aggressively increase positions following strong earnings, while the community actively debates whether the stock is primed for a major breakout or consolidation as it approaches key resistance levels. Discussions are heavily focused on the company's multi-catalyst pipeline, including the potential for upward revenue guidance, upcoming clinical readouts in lung cancer, and the potential for a long-term short squeeze.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop is experiencing significant selling pressure as investors react to concerns over slowing consumer spending and a broader downturn in the restaurant sector. While some market participants are wary of the stock's valuation and ongoing competitive headwinds, others see the recent price drop as a potential value opportunity, with the community actively debating whether the current levels represent a solid bottom or further downside risk.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is surging as investors pivot from recent earnings volatility to focus on the company's record $1.8 billion backlog and recent major satellite contract awards. The stock has seen massive volume and buying interest as market participants debate whether this momentum signals a long-term revaluation or a temporary bull trap.

Stellantis NV engages in the designing, engineering, manufacturing, distributing, and selling of vehicles and components. It offers its products under the Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep, Lancia, Maserati, Opel, Peugeot, Ram Trucks, Vauxhall, Free2move, and Leasys brands. The company was founded on April 1, 2014 and is headquartered in Hoofddorp, the Netherlands.

Stellantis N.V

Stellantis is trending as investors weigh an aggressive $70 billion turnaround plan focused on revitalizing core brands like Jeep and Ram, while the company navigates ongoing manufacturing challenges and a pivot back toward hybrid and internal combustion models. Market sentiment remains divided, with the community actively debating whether the stock's low valuation represents a deep-value opportunity or a long-term trap amidst broader auto sector headwinds and intensified competition from Chinese EV manufacturers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Merck is trending as investor interest intensifies regarding potential biotech acquisitions intended to bolster its oncology pipeline ahead of the looming patent cliff for Keytruda. The investor community is actively debating the likelihood of buyouts for companies like Sellas Life Sciences and Inhibrx, as Merck seeks to secure innovative cancer platforms to maintain its market dominance.

Dow Futures Slip, S&P 500, Nasdaq Futures Climb Ahead Of Key Retail Earnings, Fed Minutes: NLST, AVGO, LUNR, MRK Stocks In Focus

Equity

Dow futures were down 0.09%, while the S&P 500 futures climbed 0.09% and the Nasdaq-100 futures were up 0.25% at the time of writing.

Can BMY's First CELMoD Approval Support Its Growth Strategy?

Bristol Myers wins FDA accelerated approval for Zenbexus, the first CELMoD therapy, as data show it doubles MRD-negative complete response rates.

Can Keytruda Sustain Merck's Growth in the Second Half of 2026?

MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term sales momentum.

Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?

Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.

MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?

Merck's strong Keytruda sales and pipeline progress support its long-term outlook, but falling estimates and patent risks cloud the near term.

IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum

Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.

IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss

Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocking headwind cloud the near-term outlook.

BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?

Bristol Myers Squibb's Growth Portfolio and pipeline support momentum, but generic headwinds and recent gains call for a cautious stance.

IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake

Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.

PFE, MRK, SNY, MRNA In Focus As Trump Reportedly Eyes Executive Order On Vaccines And Autism

The order’s contents remain unclear, and timing could shift, Bloomberg reported, citing people familiar with the matter.


Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Bearish Sentiment

Track MRK stock price, charts, news and real-time market activity on Stocktwits. Join the MRK message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Merck & Co Inc stock.

MRK Stock Price Today - Merck & Co Inc News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$2.22	--	--	N/A
Q2 '26	-$0.27	-$0.13	51.42%	BEAT
Q1 '26	-$1.47	-$1.28	13.15%	BEAT
Q4 '25	$2.01	$2.04	1.43%	BEAT
Q3 '25	$2.35	$2.58	9.90%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings